SCHEMBL5726705

SCHEMBL5726705

O=C(O)c1ccc(CCCN(CCCc2cccc(Cl)c2)C(=O)C(F)(F)F)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.38
PLAAT3 P53816 1/20 0.38
PLAAT5 Q96KN8 1/20 0.38
PLAAT2 Q9NWW9 1/20 0.38
PLAAT4 Q9UL19 1/20 0.38
PTPRC P08575 1/20 0.38
PTPRG P23470 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
GRM5 P41594 1/20 0.38
PTGER4 P35408 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
GRM2 Q14416 1/20 0.36
GRM3 Q14832 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
PTGER2 P43116 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5727081 0.86 GRM5 (0.38) MRGPRX4HDAC3HDAC4HDAC1HDAC6
SCHEMBL5726264 0.86 SLC2A1 (0.43) MRGPRX4PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL5725353 0.85 MRGPRX4 (0.40) MRGPRX4PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL5726791 0.84 NAAA (0.46) MRGPRX4PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL5727377 0.84 TAAR1 (0.39) MRGPRX4PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL5726679 0.82 CCR5 (0.42) MRGPRX4GRM2GRM3TAAR1MEN1
SCHEMBL5725361 0.82 PLAAT3 (0.39) MRGPRX4PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL2769588 0.82 TAS2R14 (0.39) MRGPRX4PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL5046689 0.81 PLAAT3 (0.41) MRGPRX4PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL5047961 0.81 POLB (0.48) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 US claimed
EP-0946501-B1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER (US) 2006-05-31 EP disclosed
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 US disclosed
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC 2004-09-09 US disclosed
US-6649657-B2 Administering amide to treat osteoporosis PFIZER INC. 2003-11-18 US disclosed
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLEY Q (US) 2003-06-05 US disclosed
US-6492412-B2 ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. PFIZER, INC. 2002-12-10 US disclosed
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLY O (US) 2002-02-07 US disclosed
US-6344485-B1 Method for treating glaucoma PFIZER INC. 2002-02-05 US disclosed
US-6288120-B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. 2001-09-11 US disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 EP disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 MRGPRX4 332/4885PLAAT3 381/4885PLAAT5 311/4885
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 MRGPRX4 332/4885PLAAT3 381/4885PLAAT5 311/4885
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 MRGPRX4 332/4885PLAAT3 381/4885PLAAT5 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.